Record ID	
Study ID (from recruitment file)	
Date of Interview	
Interviewer Name	
Is this interview being audio-recorded?	○ Yes ○ No

Hello, my name is X and I am conducting a study funded by the National Institutes of Health that is examining clinical decision making for older adults. I would like to interview you about how clinicians make decisions about hemoglobin A1c goals for older diabetes patients. Imagine that you are seeing an 80 year woman for a diabetes follow up visit. She uses glargine insulin 45 units once daily and metformin 1000 mg twice daily for her diabetes. The hemoglobin A1c is 6.7%. She is not having symptoms of hypoglycemia. When she checks her morning glucose she gets readings between 85 and 120 mg/dl.

Please describe your approach to selecting a HbA1c treatment goal for a patient like this.

What do you do when the HbA1c is lower than your goal? Do you have an approach to de-escalating or stopping diabetic medications in older adults? Can you describe situations where you stopped or reduced a medication for diabetes?

Explain what the most important medical or non-medical factors that influence when you decide to reduce diabetes treatment? Are there specific conditions or comorbidities you use to make your decision?

Has your approach changed over the past few years?

For each of the following statements, I would like you to tell me if you: strongly agree, agree, neither agree nor disagree, disagree, strongly disagree.

Patients who have been told to keep their diabetes tightly controlled in the past believe when they need to maintain the same level of control when they are older.

- $\bigcirc$  Strongly agree
- ⊖ Agree
  - $\bigcirc$  Neither agree nor disagree
  - Disagree
  - Strongly disagree



The potential health benefits of keeping the HbA1c below 7.5 outweigh the potential harms for the average 77 year old insulin or sulfonylurea treated diabetes patient.

The potential health benefits of keeping the HbA1c below 7.0 outweigh the potential harms for the average 77 year old insulin or sulfonylurea treated diabetes patient.

The potential health benefits of keeping the HbA1c below 7.0 outweigh the potential harms for the average 85 year old insulin or sulfonylurea treated diabetes patient.

I would be concerned that if I told an older diabetes patient that I recommended letting the HbA1c go higher, he or she would be offended.

For insulin or sulfonylurea-treated patients over 75, I am usually able to tell when someone is at risk from hypoglycemia by asking about symptoms.

Most of my primary care colleagues would not reduce insulin or sulfonylurea dose for elderly patients with a HbA1c < 7 unless there were symptoms of hypoglycemia

In my experience, I have not found symptomatic hypoglycemia to be a big problem for my older insulin or sulfonylurea treated patients with diabetes.

Thank you! That is the end of the interview. We appreciate your participation. We'd like to mail you a \$50 Target gift card. What is best address to mail this to?

Interviewer notes

- Strongly agree
- ⊖ Agree
- $\bigcirc$  Neither agree nor disagree
- O Disagree
- Strongly disagree
- Strongly agree
- Agree
- $\bigcirc$  Neither agree nor disagree
- O Disagree
- Strongly disagree
- Strongly agree
- Agree
- Neither agree nor disagree
- 🔘 Disagree
- O Strongly disagree
- Strongly agree
- 🔾 Agree
- Neither agree nor disagree
- Disagree
- Strongly disagree
- ⊖ Strongly agree
- $\bigcirc$  Agree
- O Neither agree nor disagree
- Disagree
- Strongly disagree
- Strongly agree
- 🔾 Agree
- Neither agree nor disagree
- ⊖ Disagree
- $\bigcirc$  Strongly disagree
- Strongly agree
- Agree
- Neither agree nor disagree
- Disagree
- Strongly disagree

